Antimicrobial resistance, one of the world’s biggest killers, has reached an alarming tipping point.

Changing the way antibiotics are developed and accessed.

A public-health driven model to tackle AMR.

Our latest news and resources.

Protecting people from the rise and spread of drug-resistant infections.

Supporting efforts to ensure the right antibiotics are developed and reach the people who need them.

In vitro activity of zoliflodacin against Neisseria gonorrhoeae collected in the United States from 2020 to 2022

Zoliflodacin is a first-in-class spiropyrimidinetrione, oral, single-dose antibacterial recently approved by the US FDA for treatment of uncomplicated urogenital gonorrhea. Isolates of Neisseria gonorrhoeae (n = 322) collected in the United States in 2020–2022 by the Centers for Disease Control and Prevention, as well as two ceftriaxone-resistant isolates, were tested for susceptibility to zoliflodacin. All isolates were susceptible to zoliflodacin with MIC50/90 values of 0.12 µg/mL. Zoliflodacin activity was consistent over time and against ceftriaxone-, ciprofloxacin-, and tetracycline-resistant and azithromycin-non-susceptible isolates.

Authors

Sarah M. McLeod, Samir H. Moussa, Meredith Hackel, Carmen Au, Pierre Daram

READ PUBLICATION